<DOC>
	<DOCNO>NCT00360685</DOCNO>
	<brief_summary>A comparative trial patient receive daily dos tacrolimus ( TAC ) day +60 taper begin , absence graft-versus-host disease ( GVHD ) , discontinue day +180 . In addition patient randomize methotrexate ( MTX ) mycophenolate mofetil ( MMF ) , absence GVHD , taper schedule begin day +240 complete day +360 . Doses adjust maintain blood level .</brief_summary>
	<brief_title>Tacrolimus Mycophenolate Mofetil ( MMF ) GVHD Prophylactic Regimen Compared Tacrolimus Methotrexate ( MTX</brief_title>
	<detailed_description>The randomization comparative trial stratify condition regimen , patient enrol MCC-14178 , busulfan AUC level . All patient receive daily dos TAC begin day -3 ( day 0 day hematopoietic stem cell transplant ( HCT ) ) give day +60 taper begin absence GVHD . Provided GVHD develops , TAC discontinue day +180 . Doses adjust maintain blood level . In addition TAC , patient randomize one follow additional anti-GVHD medication : MTX MMF begin day 0 least 2 hour end HCT . In absence GVHD tapering schedule begin day +240 complete day +360 . Study participant extensively monitor inpatient weekly outpatient . Some test conduct least twice weekly ( blood test , toxicity data , GVHD physical exam ) one-month post-transplant tapering period 2 year .</detailed_description>
	<mesh_term>Graft v Host Disease</mesh_term>
	<mesh_term>Mucositis</mesh_term>
	<mesh_term>Methotrexate</mesh_term>
	<mesh_term>Tacrolimus</mesh_term>
	<mesh_term>Mycophenolate mofetil</mesh_term>
	<mesh_term>Mycophenolic Acid</mesh_term>
	<criteria>Patient must go T cellreplete allogeneic transplant A contraindication use tacrolimus , mycophenolate , methotrexate</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2013</verification_date>
	<keyword>Tacrolimus</keyword>
	<keyword>Methotrexate</keyword>
	<keyword>Mycophenolate mofetil</keyword>
	<keyword>Mucositis</keyword>
	<keyword>Acute graft-versus-host disease ( aGVHD )</keyword>
	<keyword>Engraftment</keyword>
	<keyword>hemolytic/uremic syndrome ( HUS )</keyword>
	<keyword>Thrombotic thrombocytopenic purpura ( TTP )</keyword>
</DOC>